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Abstract
Enterobacter species are the fourth most common cause of Gram-negative bloodstream infection (BSI). We examined temporal changes
and seasonal variation in the incidence rate of Enterobacter spp. BSI, estimated 28-day and 1-year mortality, and determined in vitro antimi-
crobial resistance rates of Enterobacter spp. bloodstream isolates in Olmsted County, Minnesota, from 1 January 1998 to 31 December
2007. Multivariable Poisson regression was used to examine temporal changes and seasonal variation in incidence rate and Kaplan–Meier
method was used to estimate 28-day and 1-year mortality. The median age of patients with Enterobacter spp. BSI was 58 years and 53%
were female. The overall age- and gender-adjusted incidence rate of Enterobacter spp. BSI was 3.3 per 100 000 person-years (95% CI
2.3–4.4). There was a linear trend of increasing incidence rate from 0.8 (95% CI 0–1.9) to 6.2 (95% CI 3.0–9.3) per 100 000 person-years
between 1998 and 2007 (p 0.002). There was no signiﬁcant difference in the incidence rate of Enterobacter spp. BSI during the warmest
4 months compared to the remainder of the year (incidence rate ratio 1.06; 95% CI 0.47–2.01). The overall 28-day and 1-year mortality
rates of Enterobacter spp. BSI were 21% (95% CI 8–34%) and 38% (95% CI 22–53%), respectively. Up to 13% of Enterobacter spp.
bloodstream isolates were resistant to third-generation cephalosporins. To our knowledge, this is the ﬁrst population-based study to
describe the epidemiology and outcome of Enterobacter spp. BSI. The increase in incidence rate of Enterobacter spp. BSI over the past
decade, coupled with its associated antimicrobial resistance, dictate the need for further investigation of this syndrome.
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Introduction
Enterobacter species are the fourth most common cause of
Gram-negative bloodstream infection (BSI) [1–3]. Population-
based studies that speciﬁcally address the epidemiology, out-
come and in vitro antimicrobial resistance rates of Enterobacter
spp. BSI are lacking and most surveys that have been pub-
lished have been derived from referral tertiary care centres
[4–10]. Therefore, we performed a population-based study to
determine the incidence rate and examine temporal changes
in the incidence rate of Enterobacter spp. BSI. In addition, we
examined seasonal variation in incidence rate of Enterobacter
spp. BSI because recent reports have demonstrated seasonal
variation in both Escherichia coli [11] and Klebsiella pneumoniae
BSI [12] and other syndromes of infections caused by
Gram-negative bacilli [13]. We also estimated the 28-day and
1-year mortality rates in patients with Enterobacter spp. BSI.
Lastly, we examined the in vitro antimicrobial resistance rates
of Enterobacter spp. bloodstream isolates in Olmsted County,
Minnesota, from 1998 to 2007.
Materials and Methods
Setting
Olmsted County is located in southeastern Minnesota and has
a population of 124 277 according to the 2000 census (US
Census Bureau, Olmsted County QuickFacts; http://quick
facts.census.gov, accessed 21 April 2008). With the exception
of a lower prevalence of injection drug use, a higher preva-
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lence of middle-class individuals and a higher proportion being
employed in the healthcare industry, the population character-
istics of Olmsted County residents are similar to those of
USA non-Hispanic whites [14,15]. The Rochester Epidemiol-
ogy Project (REP) is a unique medical records-linkage system
that encompasses care delivered to residents of Olmsted
County, Minnesota. The microbiology laboratories at Mayo
Medical Center and Olmsted Medical Center are the only two
laboratories in Olmsted County. These two medical centres
are geographically isolated from other urban centres, as previ-
ously described [14,16,17]; therefore, local residents are able
to obtain healthcare within the community, rather than seek-
ing healthcare at a distant geographic location.
Case ascertainment
We used complete enumeration of Olmsted County, Minne-
sota, from 1 January 1998 to 31 December 2007. Using the
microbiology databases at the Mayo Medical Center Roches-
ter and Olmsted Medical Center, we identiﬁed 38 unique
patients with ﬁrst episodes of monomicrobial Enterobacter
spp. BSI during the study period. Medical records were
reviewed by the primary investigator (M.N.A.) to conﬁrm
the diagnosis, determine patient residency status, and obtain
baseline clinical features and outcome.
Blood cultures were processed using standard microbiology
techniques according to the CLSI. Both laboratories are certi-
ﬁed by the College of American Pathologists. CLSI methods
were employed to evaluate in vitro antimicrobial susceptibility
results of Enterobacter spp. bloodstream isolates. The study
was approved by the institutional review boards of both insti-
tutions. The detailed case ascertainment and blood culture
methods used have been described previously [17–19].
Case deﬁnition
Monomicrobial Enterobacter spp. BSI was deﬁned as the
growth of only Enterobacter spp. in a blood culture, excluding
coagulase-negative staphylococci, Corynebacterium spp. and
Propionibacterium spp. Cases were classiﬁed according to the
site of acquisition into nosocomial, healthcare-associated and
community-acquired [20]. The primary source of BSI was
deﬁned using the Centers for Disease Control and Preven-
tion criteria [21].
Statistical analysis
Descriptive statistics were used to summarize the data: medi-
ans and interquartile range (IQR) for continuous variables
and counts and percentages for categorical variables. Fisher’s
exact test was used to evaluate associations between cate-
gorical variables and Wicoxon rank-sum test was used to test
for differences in medians across continuous variables.
The incidence rate, expressed as the number of new
cases of Enterobacter spp. BSI per 100 000 person-years, was
calculated assuming that the entire population of Olmsted
County was at risk of BSI. The 2000 Olmsted County census
ﬁgures were used to compute the age-, gender- and calendar
year-speciﬁc person-years denominator with a projected
population growth rate after 2000 of 1.9% per year. The
10-year study period was divided into ﬁve 2-year intervals
(1998–1999, 2000–2001, 2002–2003, 2004–2005 and 2006–
2007) and age was divided into ﬁve groups (0–18, 19–39,
40–59, 60–79 and ‡80 years). The incidence rate was directly
adjusted to the USA 2000 white population. A 95% CI for each
incidence rate was estimated using a Poisson distribution.
To evaluate the association between seasonal variation
and incidence rate of Enterobacter spp. BSI, the age- and gen-
der-adjusted incidence rate was calculated for both the four
warmest months (June to September) and the remaining
8 months; the person-years denominator was multiplied by
1/3 and 2/3, respectively. The incidence rate ratio is the ratio
of the incidence rate for the four warmest months relative
to the incidence rate for the remaining 8 months. A 95% CI
for the incidence rate ratio was constructed using bootstrap
resampling.
To create an additional measure of seasonal variation, the
average monthly temperatures for Rochester, Minnesota, were
obtained from historic city records (Weatherbase Historical
Weather for Rochester, MN, USA; http://www.weather
base.com, accessed 24 July 2008). Incidence rates were
calculated for each of the 12 months assuming a ﬁxed popula-
tion within a given year. To test for an association between
average monthly temperature and the incidence rate of Enterob-
acter spp. BSI at the same time as adjusting for gender, age and
calendar year, a multivariable Poisson regression model was
used.
The Kaplan–Meier method was used to estimate the 28-
day and 1-year all-cause mortality rates. Patients were fol-
lowed from the date of ﬁrst episode of Enterobacter spp. BSI
until death or last healthcare encounter; long-term follow-up
was available through the REP. Patients lost to follow-up
were censored on the date of their last healthcare encoun-
ter. All analyses were carried out using the SAS software, ver-
sion 8.2 (SAS Institute, Cary, NC, USA). p <0.05 (two-sided)
was considered statistically signiﬁcant.
Results
We identiﬁed 38 unique patients with Enterobacter spp. BSI
during the study period; 26 had Enterobacter cloacae, ten had
Enterobacter aerogenes and two had Enterobacter sakazakii BSI.
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The median age of patients with Enterobacter spp. BSI was
58 years (IQR 45–75) and 20 (53%) were female. Most cases
were healthcare-associated (58%) or nosocomial (21%); the
remaining 21% of cases were community-acquired. The uri-
nary tract was the most common identiﬁed primary source
of infection (24%), followed by the gastrointestinal tract
(18%), central venous catheter-related cases (11%), the respi-
ratory tract (5%), skin and soft tissue (5%), bone and joint
(3%), and the central nervous system (3%). Twelve patients
(32%) had primary BSI of unknown source.
The overall age- and gender-adjusted incidence rate of
Enterobacter spp. BSI was 3.3 (95% CI 2.3–4.4) per 100 000
person-years. The age-adjusted incidence rate of Enterobacter
spp. BSI per 100 000 person-years was 3.9 (95% CI 2.0–5.8)
in males and 3.2 (95% CI 1.8–4.6) in females. The incidence
rate of Enterobacter spp. BSI increased linearly with age
(p 0.007) (Fig. 1). After adjusting for gender and age, there
was a linear increase in the incidence rate of Enterobacter
spp. BSI from 1998 to 2007 (p 0.002) (Fig. 2).
The age- and gender-adjusted incidence rate of Enterobacter
spp. BSI per 100 000 person-years was 3.5 (95% CI 1.6–5.4)
during the warmest 4 months of the year (June to September)
compared to 3.3 (95% CI 2.0–4.5) during the remainder of the
year (incidence rate ratio 1.07; 95% CI 0.47–2.01). Addition-
ally, there was no association between the incidence rate of
Enterobacter spp. BSI and average temperature (p 0.83) (Fig. 3).
Patients with E. aerogenes BSI were older than those with
E. cloacae BSI (median age 74 vs. 52 years; p 0.008)
(Table 1). Additionally, patients with E. aerogenes BSI were
more likely than those with E. cloacae BSI to have a commu-
nity-acquired site of infection acquisition (60% vs. 8%;
p 0.002) and a urinary tract primary source of infection (50%
vs. 15%; p 0.08).
The age- and gender-adjusted incidence rates of E. cloacae
and E. aerogenes BSI per 100 000 person-years were 2.2
(95% CI 1.4–3.1) and 0.9 (95% CI 0.4–1.5), respectively. The
FIG. 1. Gender-adjusted incidence rates of Enterobacter species
bloodstream infection by age group, 1998–2007. Error bars indicate
the 95% CI. The p-value denotes a linear change in incidence rate
using Poisson regression.
FIG. 2. Age- and gender-adjusted incidence rates of Enterobacter
species bloodstream infection by calendar year. Error bars indicate
the 95% CI. The p-value denotes a linear change in incidence rate
using Poisson regression.
FIG. 3. Monthly age- and gender-adjusted incidence rates of Enterob-
acter species bloodstream infection and average monthly tempera-
tures, 1998–2007.
TABLE 1. Clinical characteristics of patients with Entero-
bacter species bloodstream infectiona
Variable
Enterobacter
cloacae
(n = 26)
Enterobacter
aerogenes
(n = 10)
Age, median (IQR) 52 (39–71) 74 (61–82)
Female sex, n (%) 15 (58) 4 (40)
Site of acquisition, n (%)
Community-acquired 2 (8) 6 (60)
Healthcare-associated 17 (65) 3 (30)
Nosocomial 7 (27) 1 (10)
Primary source, n (%)
Urinary tract 4 (15) 5 (50)
Gastrointestinal tract 5 (19) 1 (10)
Central venous catheter-related 4 (15) 0 (0)
Other 3 (12) 2 (20)
Unknown 10 (38) 2 (20)
IQR, interquartile range.
aA 51-year-old male and a newborn female with healthcare-associated Enterob-
acter sakazakii bloodstream infection secondary to a gastrointestinal tract source
and meningitis, respectively, are not shown.
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age-adjusted incidence rates of E. cloacae BSI were compara-
ble in males and females [2.2 (95% CI 0.8–3.5) and 2.4 (95%
CI 1.2–3.7) per 100 000 person-years, respectively]. The
incidence rates of E. aerogenes BSI for males and females
were 1.6 (95% CI 0.3–2.8) and 0.6 (95% CI 0–1.3) per
100 000 person-years, respectively.
Complete patient follow-up was obtained for most of the
cohort; no patient was lost to follow-up within 28 days and
only 3 (8%) were lost to follow-up within 1 year of Enterobact-
er spp. BSI. The overall 28-day and 1-year all-cause mortality
rates of Enterobacter spp. BSI were 21% (95% CI 8–34%) and
38% (95% CI 22–53%), respectively. Although the overall
28-day all-cause mortality rate was relatively higher in patients
with E. aerogenes as compared to those with E. cloacae
BSI [30% (95% CI 2–58%) vs. 15% (95% CI 2–29%)] (Fig. 4a),
there was no apparent difference in the long-term survival
(Fig. 4b).
The in vitro antimicrobial susceptibility rates of Enterobacter
spp. bloodstream isolates to all tested antimicrobial agents are
shown in Table 2. Among all tested b-lactams, ceftazidime and
piperacillin-tazobactam had the lowest in vitro susceptibility
rates (87% and 89%, respectively). No cefepime- or carbape-
nem-resistant Enterobacter spp. bloodstream isolates were
detected in our population over the past decade.
Discussion
To our knowledge, this is the ﬁrst population-based study to
describe the epidemiology, outcome and in vitro antimicrobial
resistance rates of Enterobacter spp. BSI. We demonstrated a
linear trend of an increasing incidence rate of Enterobacter
spp. BSI during the past decade. The age- and gender-
adjusted incidence rate of Enterobacter spp. BSI increased
from 0.8 (95% CI 0–1.9) to 6.2 (95% CI 3.0–9.3) per
100 000 person-years between 1998 and 2007. There was
no seasonal variation in the incidence rate of Enterobacter
spp. BSI.
Based on an age- and gender-adjusted incidence rate of 2.2
(95% CI 1.4–3.1) per 100 000 person-years, E. cloacae was
the fourth most common Gram-negative bacillus to cause BSI
in our population; E. coli, K. pneumoniae and Pseudomonas
aeruginosa [incidence rates of 41.4 (95% CI 37.6–45.3), 9.7
(95% CI 7.8–11.6) and 4.7 (95% CI 3.4–6.1) per 100 000
person-years, respectively] were the three most common
causes of BSI due to Gram-negative bacilli, as previously
described [11,17,22]. The incidence rate of BSI due to all four
organisms increased with age. The median age of 52 years in
patients with E. cloacae BSI was notably lower than that in
patients with E. coli, K. pneumoniae and P. aeruginosa BSI (69,
73 and 69 years, respectively). By contrast to E. coli BSI that
was more common in females [11,23], and K. pneumoniae BSI
and P. aeruginosa BSI that were more common in males
[17,22,24,25], the incidence rate of E. cloacae BSI was not
inﬂuenced by gender. Most cases of E. cloacae BSI were
healthcare-associated or nosocomial, and almost one-third
had no known primary source of infection, which is consistent
with previous studies [5,9,10,26].
(a)
(b)
FIG. 4. Kaplan–Meier 28-day (a) and 1-year (b) survival curves of
patients with Enterobacter cloacae and Enterobacter aerogenes blood-
stream infection, 1998–2007.
TABLE 2. In vitro antimicrobial susceptibility rates of Ente-
robacter species bloodstream isolates, 1998–2007
Antimicrobial
Number of
susceptible
isolates/number
of isolates tested Susceptibility (%)
Ceftazidime 33/38 87
Piperacillin-tazobactam 33/37 89
Ciproﬂoxacin 36/38 95
Levoﬂoxacin 35/37 95
Trimethoprim-sulfamethoxazole 37/38 97
Gentamicin 38/38 100
Cefepime 37/37 100
Imipenem 37/37 100
Meropenem 37/37 100
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E. aerogenes is an uncommon cause of Gram-negative BSI
with an age- and gender-adjusted incidence rate of 0.9 (95%
CI 0.4–1.5) per 100 000 person-years. Although the inci-
dence rate of E. aerogenes BSI in males was nearly three-fold
greater than that in females, the difference was not statisti-
cally signiﬁcant as a result of the small number of patients
with E. aerogenes BSI in our population. Patients with E. aer-
ogenes were older and more likely to have a urinary tract
primary source of infection than those with E. cloacae BSI,
which is consistent with the results of a recent study [27].
Our ﬁnding of an increasing incidence rate of Enterobacter
spp. BSI over the past decade is consistent with the results
of a recent investigation that demonstrated increasing fre-
quency of Enterobacter spp. as a cause of BSI in a tertiary
care centre in Spain from 1991 to 2006 [7]. It is also consis-
tent with observations of earlier paediatric studies that sug-
gested the emergence of Enterobacter spp. as an important
cause of BSI in children [28,29]. The increase in incidence
rate of Enterobacter spp. BSI in our population is unlikely to
be a result of changes in physicians’ practices in obtaining
blood cultures in febrile patients because the incidence rates
of BSI due to E. coli, Klebsiella spp., and other Gram-negative
bacilli have remained stable over the same time period
[11,19,22]. Because most cases of Enterobacter spp. BSI were
healthcare-associated or nosocomial, it is likely that changes
within the local hospitals’ environment have resulted in this
increase in incidence rate. It is conceivable that an increasing
number of patients are colonized with Enterobacter spp. after
hospital admission or contact with the healthcare setting for
an outpatient procedure such as urinary tract instrumenta-
tion, haemodialysis or outpatient chemotherapy [30]. In addi-
tion, some studies have identiﬁed previous exposure to
broad-spectrum antimicrobial agents, particularly third-gener-
ation cephalosporins, as a risk factor for Enterobacter spp.
BSI [4,9,31]. It is possible that the increasing use of these
antimicrobial agents in our local population is temporally
associated with the increase in the incidence rate of Entero-
bacter spp. BSI, although these data were not collected to
permit that determination.
Our observation of an increasing incidence rate of Entero-
bacter spp. BSI deserves additional study. Subsequent work
should determine whether the increase in incidence rate of
Enterobacter spp. BSI that was seen locally is also present in
other locales. The development of a multi-national popula-
tion-based study to examine temporal trends in Enterobacter
spp. BSI with molecular testing of bloodstream isolates
would provide vital clinical and microbiological information
to advance this ﬁeld.
Enterobacter spp. is more likely than other commonly iso-
lated Gram-negative bacilli, such as E. coli and Klebsiella spp.,
to be resistant to antimicrobial agents. For example, 13% of
Enterobacter spp. bloodstream isolates in our local area were
not susceptible to third-generation cephalosporins compared
to only 1% of both E. coli [32] and Klebsiella spp. bloodstream
isolates [22]. The increased resistance is likely due to the
inherent capability of Enterobacter spp. isolates to produce
inducible chromosomal b-lactamases, including Amp C. Even
when the isolates demonstrate in vitro antimicrobial suscepti-
bility, exposure to certain types of b-lactam antibiotics,
including cephalosporins and extended-spectrum penicillins,
can cause a transient increase or induction of Amp C pro-
duction, resulting in antimicrobial resistance and possibly a
predisposition to treatment failures [31,33,34]. It has been
demonstrated that 15–19% of Enterobacter spp. isolates
develop resistance to third-generation cephalosporins during
treatment [4,35]. Therefore, this increase in the incidence
rate of Enterobacter spp. BSI makes the choice of an empiric
antimicrobial regimen in patients with Gram-negative BSI,
when awaiting identiﬁcation of the Gram-negative bacillus,
much more difﬁcult, especially in patients with recent contact
with the healthcare system and other identiﬁable risk factors
for Enterobacter spp. BSI.
The lack of seasonal variation in the incidence rate of
Enterobacter spp. BSI in the present study is consistent with
the results of a large study from four continents [12]. How-
ever, this is in contrast to our previous work that demon-
strated a higher incidence rate of E. coli BSI during the
warmest 4 months than in the reminder of the year [11].
The factors involved in the presence or absence of seasonal
variation in BSI have yet to be identiﬁed.
Patients with E. cloacae BSI were younger than those with
E. aerogenes BSI in the present study and it is conceivable
that the younger age accounted for the lower mortality
rate in the former group. The relatively small sample size did
not permit an examination of predictors of mortality in a
multivariable model to conﬁrm this notion. The 28-day
all-cause mortality rate of 15% in patients with E. cloacae
BSI was notably lower than the short-term mortality rates
(21–69%) reported in studies extending back to the 1980s
[6,8–10,26,36,37]. In more recent studies, mortality rates of
13–15% have been described and are consistent with our
results [7,27]. We speculate that this decline in mortality
could be due to advancements in critical care and antimicro-
bial management.
The unique availability of long-term patient follow-up
through the REP resources in our population permitted an
estimation of 1-year all-cause mortality rate subsequent to
Enterobacter spp. BSI that has not been previously described.
Over one-third of patients did not survive beyond 1 year
after Enterobacter spp. BSI, and was most likely a result of
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the multiple comorbid conditions that characterized these
patients. This observation was similar to that previously
observed in patients with Klebsiella spp. BSI [22].
The in vitro antimicrobial resistance rates of Enterobacter
spp. bloodstream isolates in our population-based study were
notably lower than those reported previously from tertiary
care centres. Resistance rate to third-generation cephalo-
sporins was 13% in our study compared to 17–51% in hospi-
tal-based investigations [2,27,38–40]. Similarly, the 5%
resistance rate to ﬂuoroquinolones was also lower than pre-
viously reported rates of 8–14% from tertiary care centres
[2,27,38–41]. Carbapenem-resistance rates among Enterobact-
er spp. isolates were under 1% in both population- and
hospital-based studies [27,38,40]. The lower antimicrobial
resistance rates reported from population-based studies com-
pared to investigations from tertiary care centres were likely
the result of a referral bias that can adversely affect isolate
susceptibility data in tertiary care centres [17]. It is con-
ceivable that referral patients underwent more procedures,
antimicrobial exposure and complications that prompted
transfer to tertiary care centres and predisposed to coloniza-
tion or infection with bacteria that harboured antimicrobial
resistance.
The strength of the present study is the population-based
design and, therefore, the lack of referral bias. By contrast
to previous hospital-based studies that have estimated
the incidence rate of Enterobacter spp. BSI per the number of
admissions to a particular hospital, we determined the
incidence rate by 100 000 person-years in a well-deﬁned
population.
The present study has limitations. First, the data are
derived from one geographic area. Studies from multiple
geographic locations may provide a more comprehensive
view. Second, we did not perform pulse-ﬁeld gel electropho-
resis to investigate whether the increasing incidence rate of
Enterobacter spp. BSI was a result of clonal spread of a single
strain in the medical facilities in our region or patient-unique
strains. For example, the peak in incidence rate of Enterob-
acter spp. BSI observed in the 2006–2007 interval might have
been related to a nosocomial outbreak rather than reﬂect a
true increase in incidence rate of Enterobacter spp. BSI among
the general population. Third, the lack of seasonal variation
in Enterobacter spp. BSI might have been the result of a lack
of power because of the relatively small sample size. Finally,
the population of Olmsted County consists mainly of middle
class whites; therefore, the results obtained in the present
study may be generalized only to communities with similar
population characteristics.
In summary, Enterobacter spp. has emerged as an impor-
tant cause of Gram-negative BSI. The increase in incidence
rate of Enterobacter spp. BSI over the past 10 years should
prompt physicians to develop a higher suspicion for Entero-
bacter spp. in patients with suspect or proven BSI. Empiric
antimicrobial coverage should include coverage for these
microorganisms, particularly in patients with frequent contact
with the healthcare setting. For as yet unexplained reasons,
the more recent mortality rate in patients with Enterobacter
spp. BSI has declined.
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